Treatment of Thymic Carcinoma When Upfront Complete Resection Is Not Achievable (Masaoka-Koga Stage III–IVA)
Clinical Scenario
Masaoka-Koga Stage III–IVA | TNM Stage IIIA–IIIB–IVA
Thymic carcinoma at Masaoka-Koga stage III–IVA (corresponding to TNM stage IIIA, IIIB, or IVA) where imaging demonstrates that complete surgical resection cannot be achieved upfront, with no evidence of lymphogenous or haematogenous metastasis. Although surgery cannot be the first step, the overall intent of management remains curative.
Treatment Approach (Partial Overview)
When upfront resection is not feasible, tissue confirmation through biopsy is the first step, followed by primary cisplatin-based combination chemotherapy. For thymic carcinoma specifically, primary chemoradiotherapy represents an additional option. The complete regimen, specific drug selections, sequencing, and decision criteria are contained in the full protocol.
Clinical Goal
- Reassessment of tumour resectability after two to four cycles of chemotherapy, with the aim that the tumour becomes resectable.
References
DOI: 10.1093/annonc/mdv277
- Treatment algorithm for unresectable thymic tumour (Masaoka-Koga stage III–IVA, TNM stage IIIA–IIIB–IVA).
- If complete resection is deemed not to be achievable upfront on the basis of imaging studies, as it is frequently the case in Masaoka-Koga stage III/IVA tumours (classified as stage IIIA/T3, IIIB/T4, /IVA in the IASLC/ITMIG TNM proposed system), a biopsy should be carried out, followed by primary/induction chemotherapy as part of a curative-intent sequential strategy that integrates subsequent surgery or radiotherapy.
- Biopsy is required in all other clinical situations [IV, A]: approaches may consist of percutaneous core-needle biopsy or incisional surgical biopsy through mediastinotomy or mini-thoracotomy.
- Primary/induction chemotherapy is standard in non-resectable advanced thymic epithelial tumours [III, A].
- Cisplatin-based combination regimens should be administered; combinations of cisplatin, doxorubicin and cyclophosphamide, and cisplatin and etoposide, are the recommended options (Table 6) [III, A].
- Primary chemoradiotherapy with platin and etoposide is an option, especially for thymic carcinomas [III, B].
- Usually, two to four cycles are administered before imaging is carried out to reassess resectability of the tumour [III, A].
View source ↗